PRECOS Launches Lung In ONcology Model Atlas at AACR Annual Meeting 2012
Product News Apr 03, 2012
Preclinical Oncology Services Limited (PRECOS) has launched its Lung In ONcology model atlas (LION) at the AACR Annual meeting (Chicago, March 31st - April 4th 2012, booth #4306).
LION provides a premium bespoke collection of clinically relevant and validated lung oncology models for in vitro and in vivo drug discovery screening.
The models are of interest to leading pharmaceutical and biopharmaceutical companies looking to deliver significantly higher research productivity for their portfolio of therapeutic targets.
In collaboration with world-renowned experts, PRECOS is able to provide a unique collection of models from target identification to clinically relevant drug candidates to support effective drug discovery for lung cancers.
LION is part of the PRECOS PREdict platform for target discovery, a service that provides unique panels of patient-derived in vitro and in vivo models characterized, validated and ready to run in studies.
By utilizing the pharmacological audit trail (PhAT) to provide a rational framework for assessing the risk profile of a new agent, LION enables the collection of predictive lung models to match each step of the decision making process.
LION provides detailed pharmacological mapping of clinically relevant lung models using a proprietary 3D tumour growth assay (TGA).
The novel compounds in 3D TGAs are assessed against multiple standards of care and in combination therapies to develop a unique “map” of the lead therapeutic against the landscape of existing treatments.
Treatment decisions have traditionally been empiric and based upon tumour histology. Platinum-based chemotherapy remains the cornerstone of treatment but survival rates remain low.
As understanding develops with a continued expansion of the number of molecular compared to conventional therapies, PRECOS is able to provide further advanced and predictive in vitro and in vivo models.
The LION collection provides relevant, reproducible in vivo models to support pharmacokinetic and pharmacodynamic analysis of novel therapeutics and appropriate efficacy studies, including combination studies.
Advanced orthotropic and bioluminescent models as well as unique models of resistance enable a comprehensive analysis of potential opportunities for novel therapeutics.
“PRECOS continues to develop deeper, clinically relevant screening methods relevant to the models we hold, to produce a greater understanding of the disease state,” said Dr Martin Page, scientific consultant, PRECOS.
Dr Page continued, “Changes in gene expression and mutational status allow a greater insight into the relevance of each lung model. Our panels are designed to help our clients address their key needs and challenges by providing cutting-edge clinically relevant models that are ready to run.”